336 related articles for article (PubMed ID: 11121127)
1. IgG anti-melanocyte antibodies purified from patients with active vitiligo induce HLA-DR and intercellular adhesion molecule-1 expression and an increase in interleukin-8 release by melanocytes.
Li YL; Yu CL; Yu HS
J Invest Dermatol; 2000 Dec; 115(6):969-73. PubMed ID: 11121127
[TBL] [Abstract][Full Text] [Related]
2. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo.
al Badri AM; Foulis AK; Todd PM; Gariouch JJ; Gudgeon JE; Stewart DG; Gracie JA; Goudie RB
J Pathol; 1993 Feb; 169(2):203-6. PubMed ID: 8095298
[TBL] [Abstract][Full Text] [Related]
3. Aspirin reduces serum anti-melanocyte antibodies and soluble interleukin-2 receptors in vitiligo patients.
Zailaie MZ
Saudi Med J; 2005 Jul; 26(7):1085-91. PubMed ID: 16047057
[TBL] [Abstract][Full Text] [Related]
4. Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo.
Yu HS; Chang KL; Yu CL; Li HF; Wu MT; Wu CS; Wu CS
J Invest Dermatol; 1997 Apr; 108(4):527-9. PubMed ID: 9077486
[TBL] [Abstract][Full Text] [Related]
5. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance.
Le Poole IC; van den Wijngaard RM; Westerhof W; Das PK
Am J Pathol; 1996 Apr; 148(4):1219-28. PubMed ID: 8644862
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis of melanocytes in vitiligo results from antibody penetration.
Ruiz-Argüelles A; Brito GJ; Reyes-Izquierdo P; Pérez-Romano B; Sánchez-Sosa S
J Autoimmun; 2007 Dec; 29(4):281-6. PubMed ID: 17888626
[TBL] [Abstract][Full Text] [Related]
7. Expansion of vitiligo lesions is associated with reduced epidermal CDw60 expression and increased expression of HLA-DR in perilesional skin.
Le Poole IC; Stennett LS; Bonish BK; Dee L; Robinson JK; Hernandez C; Hann SK; Nickoloff BJ
Br J Dermatol; 2003 Oct; 149(4):739-48. PubMed ID: 14616364
[TBL] [Abstract][Full Text] [Related]
8. Vitiligo melanocytes in long-term culture show normal constitutive and cytokine-induced expression of intercellular adhesion molecule-1 and major histocompatibility complex class I and class II molecules.
Hedley SJ; Metcalfe R; Gawkrodger DJ; Weetman AP; Mac Neil S
Br J Dermatol; 1998 Dec; 139(6):965-73. PubMed ID: 9990357
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune etiology of generalized vitiligo.
Le Poole IC; Luiten RM
Curr Dir Autoimmun; 2008; 10():227-43. PubMed ID: 18460889
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical studies from vitiligo--comparison between active and inactive lesions.
Ahn SK; Choi EH; Lee SH; Won JH; Hann SK; Park YK
Yonsei Med J; 1994 Dec; 35(4):404-10. PubMed ID: 7871844
[TBL] [Abstract][Full Text] [Related]
11. Detection of serum anti-melanocyte antibodies and identification of related antigens in patients with vitiligo.
Zhu MC; Liu CG; Wang DX; Zhan Z
Genet Mol Res; 2015 Dec; 14(4):16060-73. PubMed ID: 26662399
[TBL] [Abstract][Full Text] [Related]
12. [Detection of serum autoantibodies to melanocyte and correlation between melanoma antigen recognized by T-cells and vitiligo in children].
Chen JP; Li HP; Jin SH; Zhang JT; Li J
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Oct; 29(10):2107-8, 2111. PubMed ID: 19861278
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.
van den Boorn JG; Konijnenberg D; Dellemijn TA; van der Veen JP; Bos JD; Melief CJ; Vyth-Dreese FA; Luiten RM
J Invest Dermatol; 2009 Sep; 129(9):2220-32. PubMed ID: 19242513
[TBL] [Abstract][Full Text] [Related]
14. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity.
Norris DA; Kissinger RM; Naughton GM; Bystryn JC
J Invest Dermatol; 1988 Jun; 90(6):783-9. PubMed ID: 3373009
[TBL] [Abstract][Full Text] [Related]
15. Detection of antibodies to melanocytes in vitiligo by western immunoblotting.
Hann SK; Shin HK; Park SH; Reynolds SR; Bystryn JC
Yonsei Med J; 1996 Dec; 37(6):365-70. PubMed ID: 9048487
[TBL] [Abstract][Full Text] [Related]
16. Melanocyte antigen-specific antibodies cannot be used as markers for recent disease activity in patients with vitiligo.
Kroon MW; Kemp EH; Wind BS; Krebbers G; Bos JD; Gawkrodger DJ; Wolkerstorfer A; van der Veen JP; Luiten RM
J Eur Acad Dermatol Venereol; 2013 Sep; 27(9):1172-5. PubMed ID: 22404127
[TBL] [Abstract][Full Text] [Related]
17. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C
J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311
[TBL] [Abstract][Full Text] [Related]
18. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.
Cui J; Bystryn JC
Arch Dermatol; 1995 Mar; 131(3):314-8. PubMed ID: 7887661
[TBL] [Abstract][Full Text] [Related]
19. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo.
Yu HS; Kao CH; Yu CL
J Invest Dermatol; 1993 Jun; 100(6):823-8. PubMed ID: 8496622
[TBL] [Abstract][Full Text] [Related]
20. Cytolytic antibodies to melanocytes in vitiligo.
Cui J; Arita Y; Bystryn JC
J Invest Dermatol; 1993 Jun; 100(6):812-5. PubMed ID: 8496621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
